Literature DB >> 16750467

Comparison of the time to extubation after use of remifentanil or sufentanil in combination with propofol as anesthesia in adults undergoing nonemergency intracranial surgery: a prospective, randomized, double-blind trial.

Marie-Christine Djian1, Benoit Blanchet, Florence Pesce, Alain Sermet, Monique Disdet, Vincent Vazquez, Charles Gury, François-Xavier Roux, Jean-Loup Raggueneau, Joel Coste, Luc-Marie Joly.   

Abstract

BACKGROUND: Anesthetics with a short context-sensitive half-time (ie, the time required for the effect-site concentration of an IV drug to decrease by 50% at steady state), such as the opioids remifentanil and sufentanil, are suitable for anesthesia when early neurologic assessment is desired to detect postoperative complications.
OBJECTIVE: This study compared the efficacy and safety profile of remifentanil and sufentanil in combination with propofol for anesthesia in adult patients undergoing nonemergency intracranial surgery.
METHODS: This was a prospective, randomized, double-blind study in adults aged 18 to 75 years who were scheduled to undergo a supratentorial neurosurgical procedure with a maximum anticipated duration of 480 minutes. Eligible patients had no incapacitating severe systemic disease (American Society of Anesthesiologists physical status class 1-3), and only those in whom immediate postoperative extubation was planned were included. Anesthesia was induced with propofol and either remifentanil 1 microg/kg or sufentanil 0.25 microg/kg. Propofol was continued using a target-controlled infusion (TCI) system. Maintenance infusion rates for remifentanil and sufentanil were 0.25 and 0.0025 microg.kg-1.min-1, respectively. The opioid and propofol infusions were adjusted based on hemodynamic parameters (mean arterial blood pressure, heart rate). The primary end point was the time to extubation. Secondary end points were hemodynamic stability (defined as the number of anesthetic adjustments required to maintain intraoperative hemodynamic parameters within 20% of preinduction values), postoperative IV morphine requirement, postoperative nausea/vomiting (PONV), and intraoperative anesthetic costs.
RESULTS: Sixty adults (29 remifentanil, 31 sufentanil) were included in the study. The 2 groups were similar with respect to sex, weight, indication for surgery, and duration of anesthesia. The sufentanil group was significantly older than the remifentanil group (55.3 vs 45.7 years, respectively; P=0.001). The median extubation time was similar in the remifentanil and sufentanil groups (10 minutes [interquartile range, 5-19 minutes] and 16 minutes [interquartile range, 10-30 minutes], respectively). Remifentanil was associated with the need for significantly fewer adjustments to maintain hemodynamic stability compared with sufentanil (0.8 vs 2.1; P=0.037), greater use of postoperative morphine (44.8% vs 22.6% of patients, P=0.01; mean IV morphine dose per patient: 4 vs 1.3 mg, P=0.016), and higher intraoperative opioid costs per patient euro vs euro P<0.001). The incidence of PONV did not differ significantly between groups. The total cost of intraoperative anesthetics per patient was similar in the 2 groups euro and euro as was the cost of propofol euro vs euro
CONCLUSION: In these adults undergoing nonemergency intracranial surgery, there was no significant difference in extubation time between those receiving remifentanil and sufentanil infusions adjusted based on hemodynamic parameters in combination with propofol administered by TCI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750467     DOI: 10.1016/j.clinthera.2006.04.001

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  8 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Recovery of psychomotor function after total intravenous anesthesia with remifentanil-propofol or fentanyl-propofol.

Authors:  Aki Takayama; Shigeki Yamaguchi; Kazuyoshi Ishikawa; Mio Shinozaki; Yoshiyuki Kimura; Masaru Nagao; Toshimitsu Kitajima
Journal:  J Anesth       Date:  2011-11-03       Impact factor: 2.078

3.  The optimal effect-site concentration of sufentanil for laryngeal mask insertion during induction with target-controlled propofol infusion at 4.0 μg/mL.

Authors:  Roshdi R Al-Metwalli
Journal:  Saudi J Anaesth       Date:  2014-04

4.  Comparison of recovery profiles in patients with Parkinson's disease for 2 types of neuromuscular blockade reversal agent following deep brain stimulator implantation.

Authors:  Yong-Seok Park; Jaewon Kim; Sung-Hoon Kim; Young-Jin Moon; Hye-Mee Kwon; Hee-Sun Park; Wook-Jong Kim; Seungil Ha
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

5.  Associations of Fentanyl, Sufentanil, and Remifentanil With Length of Stay and Mortality Among Mechanically Ventilated Patients: A Registry-Based Cohort Study.

Authors:  Wen Wang; Qiao He; Mingqi Wang; Yan Kang; Peng Ji; Shichao Zhu; Rui Zhang; Kang Zou; Xin Sun
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

6.  Effect of additional equipotent fentanyl or sufentanil administration on recovery profiles during propofol-remifentanil-based anaesthesia in patients undergoing gynaecologic laparoscopic surgery: a randomized clinical trial.

Authors:  Chunyuan Zhang; Ding Huang; Wei Zeng; Jian Ma; Ping Li; Qichang Jian; Jiamin Huang; Huanlong Xie
Journal:  BMC Anesthesiol       Date:  2022-04-29       Impact factor: 2.376

Review 7.  Effects of Anesthetic Management on Early Postoperative Recovery, Hemodynamics and Pain After Supratentorial Craniotomy.

Authors:  Eugenia Ayrian; Alan David Kaye; Chelsia L Varner; Carolina Guerra; Nalini Vadivelu; Richard D Urman; Vladimir Zelman; Philip D Lumb; Giovanni Rosa; Federico Bilotta
Journal:  J Clin Med Res       Date:  2015-08-23

8.  Clinical observation of different minimally invasive surgeries for the treatment of impacted upper ureteral calculi.

Authors:  Yuanhua Liu; Zhangyan Zhou; An Xia; Haitao Dai; Linjie Guo; Jiang Zheng
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.